Treatment outcomes of Her-2 positive Breast Cancer in the absence of Her-2 targeting agents at Groote Schuur Hospital, Cape Town, South Africa. Are we doing enough?
type: CreativeWork
description: Purpose: Breast Cancer has an estimated 2.3 billion cases globally. It is the second most common cause of cancer-related mortality in Sub-Saharan Africa. The addition of anti- Her-2 targeted therapy (Trastuzumab) to either adjuvant or neo-adjuvant treatment significantly improves disease-free survival and overall survival of women with early-stage Her-2 positive breast cancer. However, at Groote Schuur Hospital anti-Her-2 targeted treatment is not available. We have therefore evaluated to what extent our patients may be disadvantaged. The primary aims of this study were to evaluate the 3 and 5-year overall survival (OS) and recurrence free survival (RFS) of patients treated for Her-2 positive breast cancer at Groote Schuur Hospital. Secondary outcomes were to compare the OS and RFS of patients with hormone- receptor positive (HR+) and hormone-receptor negative (HR-) Her-2 positive (Her-2+) breast cancer. Methods: A retrospective folder review was conducted of all patients treated for Her-2 positive breast cancer between January 2016 and December 2016 at the breast oncology clinic at Groote Schuur Hospital, Cape Town. All patients with histologically proven Her-2 2+ and 3+ breast cancer stage I to III between 25 and 70 years old were included. Of the 561 patients on the hospital's electronic patient registry (EPR), 112 fulfilled the inclusion criteria and of these 87 patients were included for formal analysis due to missing folders. OS and RFS were calculated using Kaplan Meier analysis. A multivariate analysis using the Cox regression model and log rank testing was used to determine any association between OS or RFS and age, hormone receptors, or clinical stage. A p-value of <0.05 was used to determine statistical significance. Results: The cumulative OS and RFS at 3 years were 87% and 80%, respectively. The 5-year cumulative OS were 78% (Her-2 2+) and 73% (Her-2 3+) respectively. The 5-year RFS was 73%. The OS and RFS for patients with HR+ tumours were statisticall…
abstract: Purpose: Breast Cancer has an estimated 2.3 billion cases globally. It is the second most common cause of cancer-related mortality in Sub-Saharan Africa. The addition of anti- Her-2 targeted therapy (Trastuzumab) to either adjuvant or neo-adjuvant treatment significantly improves disease-free survival and overall survival of women with early-stage Her-2 positive breast cancer. However, at Groote Schuur Hospital anti-Her-2 targeted treatment is not available. We have therefore evaluated to what extent our patients may be disadvantaged. The primary aims of this study were to evaluate the 3 and 5-year overall survival (OS) and recurrence free survival (RFS) of patients treated for Her-2 positive breast cancer at Groote Schuur Hospital. Secondary outcomes were to compare the OS and RFS of patients with hormone- receptor positive (HR+) and hormone-receptor negative (HR-) Her-2 positive (Her-2+) breast cancer. Methods: A retrospective folder review was conducted of all patients treated for Her-2 positive breast cancer between January 2016 and December 2016 at the breast oncology clinic at Groote Schuur Hospital, Cape Town. All patients with histologically proven Her-2 2+ and 3+ breast cancer stage I to III between 25 and 70 years old were included. Of the 561 patients on the hospital's electronic patient registry (EPR), 112 fulfilled the inclusion criteria and of these 87 patients were included for formal analysis due to missing folders. OS and RFS were calculated using Kaplan Meier analysis. A multivariate analysis using the Cox regression model and log rank testing was used to determine any association between OS or RFS and age, hormone receptors, or clinical stage. A p-value of <0.05 was used to determine statistical significance. Results: The cumulative OS and RFS at 3 years were 87% and 80%, respectively. The 5-year cumulative OS were 78% (Her-2 2+) and 73% (Her-2 3+) respectively. The 5-year RFS was 73%. The OS and RFS for patients with HR+ tumours were statisticall…
author: Sirkhotte, Aqeela
keywords: Radiology
date published: 2024
date modified: 2026-07-22T22:22:49Z
provider: University of Cape Town
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Division of Radiology

PropertyValue
property ID: Handle
value: http://hdl.handle.net/11427/40646